Immutep CEO presentation BIO Asia-Taiwan Transcript
Hello. My name is Marc Voigt, CEO of Immutep. It's a pleasure to present to you and I would like to guide you in the next minutes through our corporate presentation.
So Immutep is a listed biotech company on the one hand side at the Australian Stock Exchange and then also in the US at NASDAQ on one key characteristic is that we are the globally leading company was one of the most promising immune checkpoints called LAG-3 lymphocyte activation, Gene three. We're active in immuno-oncology as well as in autoimmune diseases. We have four different product candidates, two of them in immuno-oncology to an autoimmune diseases.
We have, of course, a lot of data from a lot of ongoing clinical trials and our business model is to collaborate with a big pharmaceutical industry and actually we deliver on that business model already. We have partnerships with GlaxoSmithKline was Pfizer with Merck and with Novartis and others as well. Our cash position is very good.
Our last financing was in April this year, and we have a cash life about to end of calendar year
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
